trs005
zhejiang teruisi biopharmaceuticals
['trs005']
cd20+ r/r b-cell nhl | phase i study of trs005 (an anti-cd20-mmae adc) mpfs 4 months #esmo22 
NHS Haemato-Oncology Pharmacist @KingsCollegeNHS | Former Specialty Training @GSTTnhs | @NIHRresearch Internship Graduate | IPE Facilitator @KingsCollegeLon